Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $20.00

Altimmune, Inc. (NASDAQ:ALT) has earned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $20.00.

Several research firms have issued reports on ALT. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Thursday, November 14th. UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target on the stock.

Institutional Investors Weigh In On Altimmune

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALT. Price T Rowe Associates Inc. MD grew its holdings in Altimmune by 13.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company’s stock valued at $156,000 after purchasing an additional 1,821 shares during the period. California State Teachers Retirement System increased its position in shares of Altimmune by 517.7% in the 1st quarter. California State Teachers Retirement System now owns 53,730 shares of the company’s stock valued at $547,000 after buying an additional 45,032 shares in the last quarter. SG Americas Securities LLC raised its stake in Altimmune by 542.8% during the 2nd quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock worth $1,693,000 after buying an additional 214,968 shares during the period. Hennion & Walsh Asset Management Inc. bought a new position in Altimmune during the second quarter worth about $860,000. Finally, Horizon Wealth Management LLC acquired a new position in Altimmune in the second quarter valued at about $66,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Stock Up 3.5 %

Altimmune stock opened at $8.18 on Friday. The stock has a 50-day simple moving average of $7.89 and a 200 day simple moving average of $7.10. The stock has a market capitalization of $581.80 million, a price-to-earnings ratio of -5.28 and a beta of 0.15. Altimmune has a 12-month low of $5.28 and a 12-month high of $14.84.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million during the quarter. During the same period in the prior year, the firm posted ($0.39) earnings per share. As a group, sell-side analysts anticipate that Altimmune will post -1.36 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.